• In April 2026, uniQure announced plans to seek UK regulatory approval for AMT-130, its gene therapy for Huntington’s disease, supported by Phase 1/2 data indicating a very large slowing of disease progression at the high dose.
• The company also aims to meet the US FDA to discuss a potential Phase 3 trial, highlighting how AMT-130 is moving closer to a possible first-in-class treatment pathway for this rare neurodegenerative disorder.
• We’ll now examine how this move toward UK approval for AMT-130 could reshape uniQure’s investment narrative and risk profile.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

uniQure Investment Narrative Recap

To own uniQure, you need to believe AMT-130 can become a meaningful treatment for Huntington’s disease while the company manages years of losses and funding needs. The move to seek UK approval, backed by Phase 1/2 data, brings a nearer term regulatory catalyst into focus, but it also sharpens the main risk: heavy dependence on one program amid ongoing regulatory uncertainty, especially in the US.

Against this backdrop, the April 30 announcement stands out: uniQure plans a UK marketing application for AMT-130 in Q3 2026, supported by three year data showing a 75% slowing of disease progression at the high dose. This same data package will anchor an upcoming FDA Type B meeting on a potential Phase 3, making it central to both upside catalysts and the risk that regulators still require more evidence.

Yet behind the promise of a first in class gene therapy, investors should also be aware of...

uniQure's narrative projects $200.2 million revenue and $37.8 million earnings by 2029.

Uncover how uniQure's forecasts yield a $39.05 fair value, a 61% upside to its current price.

Exploring Other Perspectives

Before this UK filing news, the most optimistic analysts were already assuming revenue could reach about US$595.5 million and earnings US$165.6 million by 2029, which is a far more upbeat story than consensus and hinges heavily on AMT-130 clearing regulatory hurdles without major delays.

Explore 5 other fair value estimates on uniQure - why the stock might be worth just $33.36!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your uniQure research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free uniQure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate uniQure's overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.